Telomir Pharmaceuticals Inc (TELO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.160.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TELO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
No current thesis-health read is available for this company.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
TELO — litigation filed
Dated 2026-08-10
Regulation FD Disclosure. On August 10, 2026, Telomir Pharmaceuticals, Inc. (the “Company”) issued a press release announcing publication of a peer-reviewed preclinical study titled “Telomir-Zn Modulates Intracellular Iron and Copper to Inhibit JmjC Histone Demethylases and Suppress Tumor Growth in Prostate and Triple-Negative Breast Cancer” in the Journal of Oncology Research and Therapy, Volume 11, Issue 3. The publication demonstrated that Telomir-Zn inhibits histone demethylases (KDMs), w…
Why it matters: New partnerships could create growth chances and expand market reach.
Supportive ifA new partnership announcement with a well-known firm in the industry.
Worry ifNo new partnerships announced soon, showing no progress.
Why it matters: If the health care sector shows renewed growth, it could benefit Telomir's performance.
Supportive ifHealth care sector revenue growth accelerates back toward 10% or higher.
Worry ifSector revenue growth is slowing down below current levels.
Why it matters: A new CFO can change how the company reports finances. This could affect investor trust.
Watch forThe next quarterly report shows better financial numbers than the last quarter.
Also watch forThe next quarterly report shows more losses or worse financial numbers.
Why it matters: Better cash flow shows stronger financial health and management.
Supportive ifCash flow from operations is positive or shows big gains.
Worry ifOngoing or worse losses and negative cash flow.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$235 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $687 loss on $10,000 · 6.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,237 loss on $10,000 · 52.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Fixing the delisting notice is key. It helps keep investor trust and market access.
Worry ifA public announcement will show the delisting notice is fixed or taken back.
Less concerning ifNot fixing the delisting notice could lead to the stock being removed from exchanges.
Why it matters: Changes in leaders can change company plans and affect trust from investors.
Worry ifA new CFO has been announced. They have the right experience and plans for Telomir.
Less concerning ifThere is still uncertainty about the CFO's role and the company's direction.
Why it matters: How this lawsuit ends could affect Telomir's work and image. It matters for investors.
Worry ifA good outcome of the lawsuit that has little effect on operations.
Less concerning ifBad news or results from the lawsuit that hurt the company’s image.
Why it matters: The CFO change could impact financial management and strategy during a key growth time.
Watch forPositive financial updates or new strategies from the new CFO.
Also watch forThere are bad financial updates or issues after the CFO change.
Why it matters: More studies would show that Telomir-Zn can help treat diseases.
Supportive ifA new study shows that Telomir-Zn works in another disease model.
Worry ifNo new peer-reviewed publications will be released in the next six months.
Why it matters: Finishing this deal could help Telomir grow and improve its market position.
Supportive ifA press release confirms the TELI Pharmaceuticals deal is done.
Worry ifNews about delays or issues with the TELI Pharmaceuticals deal.
Why it matters: Starting the trial is a key step in testing Telomir-Zn for TNBC. It shows progress in clinical development.
Supportive ifThere is an official announcement about starting the Phase 1/2 trial for Telomir-Zn in TNBC.
Worry ifNo announcement of trial initiation by the end of 2026-Q3.